Pyxis Oncology raises $152m in Series B round for cancer therapies

Pyxis Oncology raises $152m in Series B round for cancer therapies

Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, and other biologics for the treatment of difficult-to-treat cancers. Pyxis Oncology’s Series B round also saw the participation of additional new investors – Perceptive […]

US medical device company Adagio Medical raises $42.5m in Series E

US medical device company Adagio Medical raises $42.5m in Series E

Adagio Medical, a California-based medical device company focused on developing treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), has raised $42.5 million in a Series E equity financing round. The company has also developed the intelligent Continuous Lesion Ablation System (iCLAS). Its Series E financing round included new investors ArrowMark Partners, Perceptive Advisors, and […]

Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round

Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round

California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 million through a Series C financing round. The Series C financing round was led by Viking Global Investors. It also saw participation from new investors such as Amzak Health, Casdin […]

Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates

Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates

Lyra Therapeutics has raised $30 million in a Series C financing round to advance its lead product candidates for the treatment of chronic rhinosinusitis (CRS). Known as an inflammatory disease of the paranasal sinuses, chronic rhinosinusitis is said to affect around 14 million people in the US. The lead product candidates of the US-based clinical-stage […]